BCTX_OUT_1 [2025-04-16 14:31:53 -0400] 4255 Bytes | 1098 tokens | Cum: 1098 tkns (13.73% of 8k)
==========================================================================

You're the expert here today. So, I pulled together a bunch of data for you to look over real fast. I'm looking at high-performance stocks today and Briacell Therapeutics (BCTX) hit my radar screen, up to 4.5850 from a prev close of 3.7500 Do you think its got more juice or is it lacking potential? It's 2:31:51 PM on Wed Apr 16, 2025 -0400 and I have to decide: buy or sell!

--- COMPANY PROFILE ---
Company: Briacell Therapeutics (BCTX)
IPO: IPO date unknown
Market Cap: $16,785,216
Shares Outstanding: 3,710,000
Industry: PHARMACEUTICAL PREPARATIONS
Exchange: XNAS
Description: BriaCell Therapeutics Corp is a clinical-stage immuno-oncology company. The group is developing an entirely new class of targeted immunotherapies to transform cancer care. Its product candidate Bria-IMT, is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC is breast cancer that has spread to other tissues). Bria-IMT is a targeted cell-based immunotherapy. The company is engaged in developing a Bria-OTS platform of personalized off-the-shelf cell-based immunotherapies. It is being evaluated in a Phase 1/2 clinical study and the treatment is initially focused on patients with breast cancer with an extension to prostate cancer, and other cancers.

Here’s a list of headlines for Briacell Therapeutics:

Today 07:30AM - BriaCell Phase 2 Survival Data Beats Leading Standard in HR+ Breast Cancer
Apr-10-25 08:00AM - BriaCell's Subsidiary, BriaPro, Develops Novel Antibodies to Anti-Cancer Target B7-H3
Mar-26-25 08:00AM - BriaCell to Present Clinical and Preclinical Data at the 2025 AACR Conference
Mar-20-25 08:00AM - Second Data Safety Monitoring Board Issues Positive Recommendation to Continue BriaCell's Phase 3 Study in Metastatic Breast Cancer
Feb-05-25 06:15PM - BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting
Feb-05-25 06:15PM 04:05PM - BriaCell Therapeutics Announces Closing of Public Offering
Feb-03-25 07:59PM - BriaCell Therapeutics Announces Pricing of Public Offering
Feb-03-25 07:59PM 04:45PM - BriaCell Therapeutics Announces Proposed Public Offering of Common Shares

Here's another list of headlines with menu handles.
I will deliver the full text of the following stories when you say their handle.
Just say, for example, B1, B2, etc.

B1 - 2025-03-26T12:00:00Z - BriaCell to Present Clinical and Preclinical Data at the 2025 AACR Conference
B2 - 2025-03-20T12:00:00Z - Second Data Safety Monitoring Board Issues Positive Recommendation to Continue BriaCell’s Phase 3 Study in Metastatic Breast Cancer
B3 - 2025-02-05T21:05:28Z - BriaCell Therapeutics Announces Closing of Public Offering
B4 - 2025-02-03T21:45:14Z - BriaCell Therapeutics Announces Proposed Public Offering of Common Shares
B5 - 2025-01-27T23:42:00Z - BriaCell Announces Completion of 15:1 Share Consolidation
B6 - 2025-01-03T22:05:00Z - BriaCell Announces Rescheduling of its Annual General Meeting of Shareholders to February 5, 2025

==============
-> THE ROLE FOR AI:
==============

1) You are the **AI analyst-investigator**, and this interaction represents a full **due diligence session** for Briacell Therapeutics (BCTX).
Due diligence includes financial data, insider trading, relevant news, and any SEC filings — and may extend beyond classic fundamentals.
Your task is to identify whether this stock has momentum and potential.

2) I am **ScanScor**, a unified report generator that archives this session as part of our real-time diligence record.

3) You will request information by referencing documents by their code.

4) As the analysis proceeds, your are encouraged to review documents until you feel confident in your judgment.
After seeing 3 sets of news articles, SEC docs, and financials, you'll be prompted to return some data pairs.

5) News articles, SEC filings, and key metrics will be revealed in subsequent prompts.

Stay focused. Gather evidence. Continue until your conclusions are clear.
Restrict all your responses to just 3 tokens until the summary and data pairs at the end.

NEXT: Request a document with its reference code(s), such as:
- `B1`, `B2`, `B3`, etc.
- To load a new set of information and menu options, reply with: `NEX`

BCTX_OUT_3 [2025-04-16 14:31:54 -0400] 851 Bytes | 233 tokens | Cum: 1333 tkns (16.66% of 8k)
==========================================================================

Showing B1 (chunk 1 of 1): B1:
**BriaCell to Present Clinical and Preclinical Data at the 2025 AACR Conference**Date: Unknown DateSource: Unknown SourceURL: https://www.globenewswire.com/news-release/2025/03/26/3049653/0/en/BriaCell-to-Present-Clinical-and-Preclinical-Data-at-the-2025-AACR-Conference.htmlBriaCell Therapeutics, a clinical-stage biotechnology company, will present three posters at the 2025 American Association for Cancer Research (AACR) Annual Meeting. The posters will cover topics related to their cancer immunotherapy pipeline, including Bria-ABC1, Bria-IMT, and Bria-OTS+.

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

BCTX_OUT_5 [2025-04-16 14:31:54 -0400] 998 Bytes | 311 tokens | Cum: 1646 tkns (20.57% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-04-16T11:52:30Z - BriaCell Phase 2 Survival Data Beats Leading Standard in HR+ Breast Cancer...
A2 - 2025-04-16T11:53:10Z - BriaCell Phase 2 Survival Data Beats Leading Standard in HR+ Breast Cancer | Taiwan News | Apr. 16, ...
A3 - 2025-04-10T12:32:51Z - BriaCell's Subsidiary, BriaPro, Develops Novel Antibodies to Anti-Cancer Target B7-H3...
A4 - 2025-04-10T12:25:31Z - BriaCell's Subsidiary, BriaPro, Develops Novel Antibodies to Anti-Cancer Target B7-H3 | Taiwan News ...
A5 - 2025-04-10T12:00:00Z - BriaCell's Subsidiary, BriaPro, Develops Novel Antibodies to Anti-Cancer Target B7-H3 - BriaCell The...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

BCTX_OUT_7 [2025-04-16 14:31:55 -0400] 1185 Bytes | 334 tokens | Cum: 1982 tkns (24.77% of 8k)
==========================================================================

Showing A1 (chunk 1 of 9): A1:
**BriaCell Phase 2 Survival Data Beats Leading Standard in HR+ Breast Cancer**Date: 2025-04-16Source: {'uri': 'manilatimes.net', 'dataType': 'news', 'title': 'The Manila times'}URL: https://www.manilatimes.net/2025/04/16/tmt-newswire/globenewswire/briacell-phase-2-survival-data-beats-leading-standard-in-hr-breast-cancer/2093472Geomega and Rio Tinto provide update on bauxite residue valorization pilot

Median overall survival of 17.3 months in Bria-IMT™ treated patients with hormone receptor positive (HR+) metastatic breast cancer markedly exceeds historical data of 14.4 months in TRODELVY® (sacituzumab govitecan-hziy) in similar heavily pre-treated patientsSurvival data in triple negative breast cancer patients treated with the BriaCell regimen was comparable to TRODELVY® No Bria-IMT related discontinuations reported to date

PHILADELPHIA and VANCOUVER, British Columbia, April 16, 20

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

BCTX_OUT_9 [2025-04-16 14:31:58 -0400] 1182 Bytes | 313 tokens | Cum: 2297 tkns (28.71% of 8k)
==========================================================================

Showing A1 (chunk 2 of 9): 25 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, announces new positive survival data in its Phase 2 study of Bria-IMT plus check point inhibitors (CPI), outperforming ADC drugs in hormone receptor positive (HR+) metastatic breast cancer (MBC) patients.

In BriaCell's Phase 2 clinical study in late-stage MBC, 25 of 37 patients treated with the ongoing pivotal Phase 3 Bria-IMT formulation were identified as having HR+ breast cancer. As shown in Table 1, the survival data of these 25 patients (17.3 months) exceeds those of the current ADC standard of care TRODELVY® (14.4 months). The survival data for the Bria-IMT regimen + immune check point inhibitor in the triple negative breast cancer (TNBC), characterized by the absence

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

BCTX_OUT_11 [2025-04-16 14:31:58 -0400] 1183 Bytes | 282 tokens | Cum: 2581 tkns (32.26% of 8k)
==========================================================================

Showing A1 (chunk 3 of 9): of estrogen (ER), progesterone (PR) and human epidermal growth factor (HER2) receptors, was similar to TRODELVY® but still markedly higher (70%) than those of chemotherapy.

"We are truly impressed with the survival benefit data of the regimen that exceeds or meets those of TRODELVY® in HR+ and TNBC metastatic breast cancer patients, respectively. Bria-IMT appears to be very well-tolerated," stated Dr. William V. Williams, BriaCell's President and CEO. "We look forward to further confirming this clinical data in our ongoing pivotal Phase 3 study with overall survival as its primary endpoint."

"HR+ and TNBC metastatic breast cancer represent a significant proportion of the patient population and are the most difficult patient groups to treat. They have limited therapeutic options and overall survival of only a few months," commented Dr. Giuseppe Del Priore, BriaCell's Chief Medical Offic

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

BCTX_OUT_13 [2025-04-16 14:32:01 -0400] 1184 Bytes | 316 tokens | Cum: 2899 tkns (36.24% of 8k)
==========================================================================

Showing A1 (chunk 4 of 9): er. "Our clinical data supports our hypothesis that the Bria-IMT regimen + CPI has the potential to address the unmet medical needs of HR+ and TNBC MBC patients and provide an effective and well-tolerated therapeutic option."

Get the latest news

delivered to your inbox Sign up for The Manila Times newsletters By signing up with an email address, I acknowledge that I have read and agree to the Terms of Service and Privacy Policy.

Table 1: Comparable Analysis of median overall survival (estimated using the Kaplan-Meier method) for the BriaCell Phase 2 study of BriaCell's Bria-IMT™ plus CPI versus other drugs in MBC patient subsets

ReferenceBreast Cancer Advertisement

Type

Median # of prior

lines of therapy

Median OS

(months)

Bria-IMT plus CPI*HR+617.3TRODELVY®1

(sacituzumab govitecan-hziy)

Advertisement

HR+414.4Single agent

chemotherapy

411.3 Bria-IMT plus CPI*TNBC611.4TRODE

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

BCTX_OUT_15 [2025-04-16 14:32:02 -0400] 1182 Bytes | 307 tokens | Cum: 3208 tkns (40.10% of 8k)
==========================================================================

Showing A1 (chunk 5 of 9): LVY®1

(sacituzumab govitecan-hziy)

TNBC3**11.8Single agent Advertisement

chemotherapy

3**6.9* Patients treated with the Phase 3 formulation

** Number of prior chemotherapy-containing regimens

1. https://www.gilead.com/-/media/files/pdfs/medicines/oncology/trodelvy/trodelvy_pi.pdf Abbreviations:

HR+: hormone receptor-positive

TNBC: Triple-negative breast cancer (lacks the estrogen receptor, progesterone receptor, and lacks or has low levels of human epidermal growth factor receptor 2 (HER2))

Advertisement

The Phase 2 study enrolled 54 heavily pre-treated metastatic breast cancer patients (median number of prior treatments = 6) who received the Bria-IMT regimen plus checkpoint inhibitor. Of these 54 patients, 37 were treated with the formulation currently being used in BriaCell's ongoing pivotal Phase 3 study in metastatic breast cancer (listed on ClinicalTrials.gov as NCT0607261

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

BCTX_OUT_17 [2025-04-16 14:32:03 -0400] 1181 Bytes | 280 tokens | Cum: 3490 tkns (43.62% of 8k)
==========================================================================

Showing A1 (chunk 6 of 9): 2). No Bria-IMT related discontinuations have been reported to date.

About BriaCell Therapeutics Corp.

BriaCell is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. More information is available at https://briacell.com/.

Safe Harbor

Advertisement

-- disclaimer trimmed -- that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "aim," "should," "will," "would," or the negative of these words or other similar expressions, although not all forward-looking st

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

BCTX_OUT_19 [2025-04-16 14:32:04 -0400] 1185 Bytes | 267 tokens | Cum: 3759 tkns (46.99% of 8k)
==========================================================================

Showing A1 (chunk 7 of 9): atements contain these words. Forward-looking statements, including statements about: BriaCell further confirming positive clinical data in its ongoing pivotal Phase 3 study; BriaCell's further clinical development of Bria-IMT™; the Company's beliefs regarding the results of BriaCell's pivotal Phase 3 study; and the Company's beliefs that the Bria-IMT™ regimen + CPI has the potential to address the unmet medical needs of HR+ and TNBC MBC patients and provide an effective and well-tolerated therapeutic option, are based on BriaCell's current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully under the heading "Risks and Uncertainties" in the Com

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

BCTX_OUT_21 [2025-04-16 14:32:04 -0400] 1181 Bytes | 258 tokens | Cum: 4019 tkns (50.24% of 8k)
==========================================================================

Showing A1 (chunk 8 of 9): pany's most recent Management's Discussion and Analysis, under the heading "Risk Factors" in the Company's most recent Annual Information Form, and under "Risks and Uncertainties" in the Company's other filings with the Canadian securities regulatory authorities and the U.S. Securities and Exchange Commission, all of which are available under the Company's profiles on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov. Forward-looking statements contained in this announcement are made as of this date, and BriaCell Therapeutics Corp. undertakes no duty to update such information except as required under applicable law.

Neither the Toronto Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contact Information

Company Contact:

Advertisement

W

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

BCTX_OUT_23 [2025-04-16 14:32:05 -0400] 405 Bytes | 115 tokens | Cum: 4136 tkns (51.70% of 8k)
==========================================================================

Showing A1 (chunk 9 of 9): illiam V. Williams, MD

President & CEO

1-888-485-6340

[email protected]

Investor Relations Contact:

[email protected]

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

BCTX_OUT_25 [2025-04-16 14:32:08 -0400] 1085 Bytes | 316 tokens | Cum: 4454 tkns (55.67% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S1 - 2025-03-12 10-Q PART I-FIN INFO

Item 1. Fin Stmnts

BRIACELL THERAPEUTICS CORP.

UNAUDITED COND CONS BAL SHEETS

January 31, 2025 July 31, 2024 ASSETS CURRENT ASSETS: Cash and cash equiv $ 5,013,654 $ 862,089 Amounts receivable and prepaid exp...

S2 - 2025-03-12 8-K Item 7.01 Regulation FD Disclosure.

On March 12, 2025, BriaPro Therapeutics Corp., a two-third (2/3) owned subsidiary of BriaCell Therapeutics Corp. (the Company), filed its unaudited condensed interim CONS financial statements and managements discussion and analysis fo...

S3 - 2025-02-05 8-K Item 1.01 Entry into a Material Definitive Agrmt.

On February 3, 2025, BriaCell Therapeutics Corp. (the Company) entered into a Placement Agency Agrmt (the Agrmt) with ThinkEquity LLC (the Placement Agent), pursuant to which the Company agreed to issue and sell dire...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

BCTX_OUT_27 [2025-04-16 14:32:09 -0400] 1181 Bytes | 380 tokens | Cum: 4836 tkns (60.45% of 8k)
==========================================================================

Showing S1 (chunk 1 of 6): S1:
PART I-FINANCIAL INFORMATION

Item 1. Financial Statements

BRIACELL THERAPEUTICS CORP.

UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS

January 31, 2025 July 31, 2024 ASSETS CURRENT ASSETS: Cash and cash equivalents $ 5,013,654 $ 862,089 Amounts receivable and prepaid expenses 2,148,919 2,791,765 Total current assets 7,162,573 3,653,854 NON-CURRENT ASSETS: Equity investment in BC Therapeutics 454,391 418,490 Intangible assets, net 192,160 199,796 Property and equipment, net 342,497 388,175 Long term prepaid expenses 1,211,946 1,211,946 Total non-current assets 2,200,994 2,218,407 Total assets $ 9,363,567 $ 5,872,261 LIABILITIES AND SHAREHOLDERS EQUITY CURRENT LIABILITIES: Trade payables $ 5,003,239 $ 7,170,781 Accrued expenses and other payables 227,599 290,376 Total current liabilities 5,230,838 7,461,157 NON-CURRENT LIABILITIES: Warrant liability 905,838 1,096,036 Total non-

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

BCTX_OUT_29 [2025-04-16 14:32:09 -0400] 1181 Bytes | 381 tokens | Cum: 5219 tkns (65.24% of 8k)
==========================================================================

Showing S1 (chunk 2 of 6): current liabilities 905,838 1,096,036 SHAREHOLDERS EQUITY (DEFICIT) (1) : Share Capital of no par value - Authorized: unlimited at January 31, 2025 and July 31, 2024, Issued and outstanding: 2,946,940 shares January 31, 2025 and 1,218,984 July 31, 2024, respectively (1) 85,451,119 72,166,414 Share-based payment reserve (1) 10,091,325 9,189,261 Warrant Reserve (1) 5,736,454 1,844,296 Accumulated other comprehensive loss (1) ( 138,684 ) ( 138,684 ) Non-controlling Interest (1) ( 376,031 ) ( 302,522 ) Accumulated deficit (1) ( 97,537,292 ) ( 85,443,697 ) Total shareholders equity (deficit) (1) 3,226,891 ( 2,684,932 ) Total liabilities and shareholders equity (deficit) $ 9,363,567 $ 5,872,261

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

BRIACELL THERAPEUTICS CORP.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHE

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

BCTX_OUT_31 [2025-04-16 14:32:10 -0400] 1181 Bytes | 422 tokens | Cum: 5643 tkns (70.54% of 8k)
==========================================================================

Showing S1 (chunk 3 of 6): NSIVE LOSS FOR THE THREE AND SIX MONTHS ENDED JANUARY 31, 2025

(Unaudited)

2025 2024 2025 2024 Three months ended January 31, Six months ended January 31, 2025 2024 2025 2024 (Unaudited) (Unaudited) (Unaudited) (Unaudited) Operating Expenses: Research, development, and clinical trial expenses $ 5,684,777 $ 8,257,455 $ 9,350,118 $ 15,114,712 General and administrative expenses 1,484,666 1,571,991 2,972,157 3,217,762 Total operating expenses 7,169,443 9,829,446 12,322,275 18,332,474 Operating loss ( 7,169,443 ) ( 9,829,446 ) ( 12,322,275 ) ( 18,332,474 ) Financial expenses, net 67,358 81,628 79,072 261,450 Change in fair value of the warrant liability 806,841 ( 1,567,747 ) 190,198 12,714,331 Share of loss on equity investment ( 42,584 ) ( 18,345 ) ( 114,099 ) ( 18,345 ) Net loss for the period $ ( 6,337,828 ) $ ( 11,333,910 ) $ ( 12,167,104 ) ( 5,375,038 ) Net loss attributable to non

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

BCTX_OUT_33 [2025-04-16 14:32:11 -0400] 1181 Bytes | 369 tokens | Cum: 6014 tkns (75.17% of 8k)
==========================================================================

Showing S1 (chunk 4 of 6): -controlling interest ( 46,408 ) ( 39,307 ) ( 73,509 ) ( 81,978 ) Net loss and Comprehensive loss for the period attributable to BriaCell ( 6,291,420 ) ( 11,294,603 ) ( 12,093,595 ) ( 5,293,060 ) Net loss per share attributable to BriaCell basic and diluted $ ( 2.33 ) $ ( 10.64 ) $ ( 5.44 ) $ ( 5.04 ) Weighted average number of shares used in computing net basic earnings per share of common stock (1) 2,699,566 1,065,448 2,224,979 1,065,448 Weighted average number of shares used in computing net diluted earnings per share of common stock (1) 2,699,566 1,065,448 2,224,979 1,065,448

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

BRIACELL THERAPEUTICS CORP.

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS EQUITY (DEFICIT)

(Unaudited)

FOR THE THREE AND SIX MONTHS ENDED JANUARY 31, 2025

Number Amount capital

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

BCTX_OUT_35 [2025-04-16 14:32:12 -0400] 1181 Bytes | 392 tokens | Cum: 6408 tkns (80.10% of 8k)
==========================================================================

Showing S1 (chunk 5 of 6): reserve loss deficit Interest (deficit) Share capital Additional paid in Warrant Accumulated other comprehensive Accumulated Non- Controlling Total

shareholders equity

Number Amount capital reserve loss deficit Interest (deficit) Balance, October 31, 2024 2,412,216 $ 82,040,741 $ 9,456,232 $ 3,930,221 $ ( 138,684 ) $ ( 91,245,872 ) $ ( 329,623 ) $ 3,713,015 Issuance of Options - - 635,093 - - - - 635,093 Exercise of warrants 41,391 796,690 - ( 268,925 ) - - - 527,765 Issuance of units 493,333 2,613,688 - 2,075,158 - - - 4,688,846 Net loss for the period - - - - - ( 6,291,420 ) ( 46,408 ) ( 6,337,828 ) Balance, January 31, 2025 2,946,940 $ 85,451,119 $ 10,091,325 $ 5,736,454 $ ( 138,684 ) $ ( 97,537,292 ) $ ( 376,031 ) $ 3,226,891

Share capital Additional paid in Warrant Accumulated other comprehensive Accumulated Non- Controlling Total

shareholders equity

Number Amount capit

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

BCTX_OUT_37 [2025-04-16 14:32:12 -0400] 790 Bytes | 292 tokens | Cum: 6702 tkns (83.78% of 8k)
==========================================================================

Showing S1 (chunk 6 of 6): al reserve loss deficit Interest (deficit) Balance, July 31, 2024 1,218,984 $ 72,166,414 $ 9,189,261 $ 1,844,296 $ ( 138,684 ) $ ( 85,443,697 ) $ ( 302,522 ) $ ( 2,684,932 ) Issuance of Options - - 902,064 - - - - 902,064 Exercise of prefunded warrants 6,666 - - - - - - - Exercise of broker warrants 64,391 1,239,367 - ( 418,352 ) - 821,015 Issuance of units 1,656,899 12,045,338 - 4,310,510 - - - 16,355,848 Net loss for the period - - - - - ( 12,093,595 ) ( 73,509 ) ( 12,167,104 ) Balance, January 31...

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

BCTX_OUT_39 [2025-04-16 14:32:20 -0400] 5847 Bytes | 1559 tokens | Cum: 8263 tkns (103.29% of 8k)
==========================================================================

This is our set of metrics for Briacell Therapeutics.
Please analyze the numbers.

+---------------------+-----------------------+-----------------------+----------------------+
| Volume: 19,084,336 | Perf Month: 10.57% | Option/Short: No / No | Sales Y/Y TTM: - |
+---------------------+-----------------------+-----------------------+----------------------+
| Avg Volume: 352.85K | Perf Quarter: -28.48% | Short Float: 5.53% | ROE: -490.69% |
+---------------------+-----------------------+-----------------------+----------------------+
| Rel Volume: 72.44 | Index: - | Short Ratio: 0.54 | ROI: -321.74% |
+---------------------+-----------------------+-----------------------+----------------------+
| RSI (14): 53.91 | Market Cap: 15.92M | Short Interest: 0.19M | Sales Surprise: - |
+---------------------+-----------------------+-----------------------+----------------------+
| ATR (14): 0.52 | Shs Outstand: 3.71M | Beta: 1.37 | EPS Surprise: 91.99% |
+---------------------+-----------------------+-----------------------+----------------------+
| SMA20: 6.88% | Shs Float: 3.47M | Sales Q/Q: - | P/E: - |
+---------------------+-----------------------+-----------------------+----------------------+
| SMA50: 7.91% | Inst Own: 12.25% | Sales past 5Y: 0.00% | Earnings: Mar 12 BMO |
+---------------------+-----------------------+-----------------------+----------------------+
| SMA200: -52.84% | Insider Own: 6.47% | Employees: 18 | |
+---------------------+-----------------------+-----------------------+----------------------+
| Perf Week: 4.13% | Insider Trans: 0.00% | Debt/Eq: 0.00 | |
+---------------------+-----------------------+-----------------------+----------------------+

The next section covers any insider trading by Briacell Therapeutics officers or majority shareholders (if available).

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 0, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': -11723614.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 4.5613
Average Volume: 900440.65
30-Day High: 4.5613
30-Day Low: 3.47

[Detailed Financials: Q2 2025]
- Total Assets: $9,363,567.0
- Total Liabilities: $6,136,676.0
- Total Equity: $3,226,891.0
- Current Assets: $7,162,573.0
- Current Liabilities: $5,230,838.0

[Income Statement: Q2 2025]
- Revenue: $0.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -2.33

[Cash Flow Statement: Q2 2025]
- Net Cash Flow: $-5,920,222.0

[Detailed Financials: Q1 2025]
- Total Assets: $10,414,330.0
- Total Liabilities: $-3,713,015.0
- Total Equity: $3,713,015.0
- Current Assets: $8,219,095.0
- Current Liabilities: $4,988,636.0

[Income Statement: Q1 2025]
- Revenue: $0.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -0.22

[Cash Flow Statement: Q1 2025]
- Net Cash Flow: $-6,955,076.0
==== END OF FINANCIAL REPORT ====

You are now requested to write a summary analysis of Briacell Therapeutics (BCTX).

Please complete the report using the exact format:
FIELD[value]

1) BRIEF_SUMMARY[]
One well-worded paragraph summarizing your findings about Briacell Therapeutics.

2) MARKET_SCORE[]
This conversation was initiated because BCTX is currently experiencing upward price and volume movement.
Estimate a number between 1–100 based on the likelihood of a continued upward price move for BCTX.
Weigh relevant data — news, filings, fundamentals, and metrics — and assign appropriate weight.

3) PRICE_TARGET[]
Suggest a price, based on all prior evidence and past price behavior, BCTX could reach in the current or upcoming trading sessions (1–5 days).
For example, if you expect BCTX to increase 50% from its current price of $0.00, say: PRICE_TARGET[0.0]

4) AI_RPT_HEADLINE[]
Write a thought-provoking 8–12 word headline summarizing this report.

5) SQUEEZE_POTENTIAL[]
Give a score from 1 to 100 representing the potential for this stock to become an active short squeeze play.
Be honest and unbiased. Consider short interest/float, price movement, volume, news strength, and volatility potential.

6) TAGS[]
List 3–6 comma-separated tags (e.g., biotech, earnings beat, squeeze setup)

7) STOCK_TYPE[]
Choose the most accurate classification: growth, value, turnaround, hype, squeeze, dividend, speculative, or other.

8) PRIMARY_CATALYST[]
e.g., earnings report, FDA approval, partnership, etc.

9) SENTIMENT[]
bullish, bearish, neutral, or mixed

10) IMPROVEMENT_SUGGESTION[]
If you believe some key info was missing, state what would have significantly improved your analysis of Briacell Therapeutics.

11) ETHICAL_RATING[]
Rate Briacell Therapeutics’s alignment with long-term shareholder interests, using a letter grade from A (high alignment) to F (low alignment).
Base this on actions such as insider buying/selling, share dilution, follow-through on public statements, and compensation practices.

12) UPCOMING_CATALYST[]
Specify any upcoming events you expect would be a catalyst affecting the share-price of Briacell Therapeutics.
Provide any reasons you can use to support it.

Return only: FIELD[value] for each of the above 12 questions.
Respond with all data pairs. Take your best guess if you have to, but don't leave blank items.
Do not explain your answers. Return only the required fields in the exact format shown.

Finally, thank you for participating!

BCTX_IN_41 [2025-04-16 14:32:20 -0400] 126 Bytes | 29 tokens | Cum: 8507 tkns (106.34% of 8k)
==========================================================================

====================================
[2025-04-16 14:32:20] # Analysis Completed
Elapsed Time: 29.15 seconds